Emilio Matt

Corporate Officer/Principal at MICROSOFT CORPORATION

Technology Services

Health Technology

Profile

Emilio Matt has worked in business development and served as a member of the board of overseers for the Alzheimer's Drug Discovery Foundation.
He is currently employed as a Business Development Director at Microsoft Corp.
and also serves as a Member-Board of Overseers at the Alzheimer's Drug Discovery Foundation.

Emilio Matt active positions

Companies	Position	Start
MICROSOFT CORPORATION	Corporate Officer/Principal	-
Alzheimers Drug Discovery Foundation Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr.	Director/Board Member	-

All active positions of Emilio Matt

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Emilio Matt's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
MICROSOFT CORPORATION	Technology Services

Private companies	1
Alzheimers Drug Discovery Foundation Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr.	Health Technology